DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration; Pcas-Nanosyn, LLC

By Notice dated January 30, 2012, and published in the **Federal Register** on February 6, 2012, 77 FR 5847, PCAS-Nanosyn, LLC, 3331–B Industrial Drive, Santa Rosa, California 95403, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Amphetamine (1100)	

The company is a contract manufacturer. At the request of the company's customers, it manufactures derivatives of controlled substances in bulk form only.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of PCAS-Nanosyn, LLC. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated PCAS-Nanosyn, LLC. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the

company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: May 15, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012–12820 Filed 5–24–12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration; Siemens Healthcare Diagnostics, Inc.

By Notice dated January 26, 2012, and published in the **Federal Register** on February 6, 2012, 77 FR 5847, Siemens Healthcare Diagnostics Inc., 100 GBC Drive, Mail Stop 514, Newark, Delaware 19702, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Tetrahydrocannabinols (7370) Ecgonine (9180) Morphine (9300)	

The company plans to produce the listed controlled substances in bulk to be used in the manufacture of reagents and drug calibrator controls which are DEA exempt products.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and

determined that the registration of Siemens Healthcare Diagnostics Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Siemens Healthcare Diagnostics Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: May 15, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012–12822 Filed 5–24–12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration; Sigma Aldrich Research Biochemicals, Inc.

By Notice dated January 26, 2012, and published in the **Federal Register** on February 6, 2012, 77 FR 5847, Sigma Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, Massachusetts 01760–2447, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Cathinone (1235)	ı
Cathinone (1235) Methcathinone (1237)	1
4-methyl-N-methylcathinone (1248)	1
Aminorex (1585)	1
Alpha-ethyltryptamine (7249)	1
Lysergic acid diethylamide (7315)	I
4-methyl-N-methylcathinone (1248) Aminorex (1585) Alpha-ethyltryptamine (7249) Lysergic acid diethylamide (7315) 3,4-methylenedioxypyrovalerone (7535)	1
3,4-methylenedioxy-N-methylcathinone (7540)	1
Tetrahydrocannabinols (7370)	1
4–Bromo-2,5-dimethoxyamphetamine (7391)	I
4–Bromo-2.5-dimethoxyphenethylamine (7392)	I
2,5-Dimethoxyamphetamine (7396) 3,4-Methylenedioxyamphetamine (7400) N-Hydroxy-3,4-methylenedioxyamphetamine (7402)	I
3,4-Methylenedioxyamphetamine (7400)	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)	I
3,4–Methylenedioxy-N-ethylamphetamine (7404)	I
3,4-Methylenedioxymethamphetamine (7405)	Į Į
Psilocybin (7437)	i I

Drug	Schedule
i–Methoxy-N,N-diisopropyltryptamine (7439)	ī
-[1-(2–Thienyl)cyclohexyl]piperidine (7470)	i
N-Benzylpiperazine (7493)	i
Heroin (9200)	i
Vormorphine (9313)	i
Amphetamine (1100)	i II
Methamphetamine (1105)	ii
Vabilone (7379)	ii
-Phenylcyclohexylamine (7460)	ii
Phencyclidine (7471)	ii
Cocaine (9041)	ii
Codeine (9050)	ii
Diprenorphine (9058)	ii
Ecgonine (9180)	ii
evomethorphan (9210)	ii
evorphanol (9220)	ii
Meperidine (9230)	ii
Metazocine (9240)	ii
Methadone (9250)	ii
Morphine (9300)	ii
Thebaine (9333)	ii
evo-alphacetylmethadol (9648)	ii
Remifentanil (9739)	ii
Sufentanii (9740)	ii
Carfentanii (9743)	ii
Fentanyl (9801)	ii

The company plans to manufacture reference standards.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Sigma Aldrich Research Biochemicals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Sigma Aldrich Research Biochemicals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the

company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: May 15, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-12821 Filed 5-24-12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration; Mallinckrodt LLC

By Notice dated January 23, 2012, and published in the **Federal Register** on January 31, 2012, 77 FR 4828, Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Tetrahydrocannabinols (7370)	I
Codeine-N-oxide (9053)	I
Dihydromorphine (9145)	I
Difenoxin (9168)	1
Morphine-N-oxide (9307)	1
Morphine-N-oxide (9307)	1
Norlevorphanol (9634)	1
Amphetamine (1100)	П
Methamphetamine (1105)	П
Methylphenidate (1724)	П
Nabilone (7379)	П
4–Anilino-N-phenethyl-4-piperidine (8333)	ii
Codeine (9050)	ii
Dihydrocodeine (9120)	II
Oxycodone (9143)	ii
Hydromorphone (9150)	ii
Hydromorphone (9150)	ii
Ecgonine (9180)	ii
Hydrocodone (9193)	ii
Levorphanol (9220)	ii
Meperidine (9230)	lii
Methadone (9250)	ii
Methadone intermediate (9254)	ii
Methadore internediate (3254)	1 11